CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
Zacks·3d ago
More News
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
Zacks·4d ago
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Zacks·4d ago
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
Zacks·5d ago
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Zacks·6d ago
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Zacks·7d ago
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
Zacks·7d ago
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
Zacks·11d ago
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Zacks·11d ago
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.